Concepedia

Ivy Fearen

IF

Statistics

Publications

10

Citations

1.2K

H-Index

10

Active since

2006

Affiliations

Dana-Farber Cancer Institute(Current)

South Texas Accelerated Research Therapeutics

Royal Marsden NHS Foundation Trust

Harvard University

Merck (Japan)

Ivy Fearen is an author at Dana-Farber Cancer Institute specializing in tumor biology, medicine, and oncology.

Top concepts

Publications per year

2006–2014

10

Publications

10

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Timothy A. Yap, Yan Li, Amita Patnaik et al. · Journal of Clinical Oncology · 2011 · 539 citations

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias

D. J. Deangelo, Richard M. Stone, L. B. Silverman et al. · Journal of Clinical Oncology · 2006 · 226 citations

, , +18

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Paul G. Richardson, Constantine Mitsiades, Kathleen Colson et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 191 citations

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Timothy A. Yap, Yan Li, Amita Patnaik et al. · Clinical Cancer Research · 2014 · 79 citations

A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST)

Anthony W. Tolcher, Tami Yap, Ivy Fearen et al. · Journal of Clinical Oncology · 2009 · 63 citations

, , +18

1–5 of 10